Company Overview of Synthetic Genomics, Inc.
Synthetic Genomics, Inc., a synthetic biology company, develops and commercializes genomic-driven solutions and products for various industries worldwide. The company focuses on various commercialization programs, including developing synthetic DNA products, tools, and instruments for organizations with demands for large and/or complex DNA constructs; algae based food and nutritional products, and biofuels; and synthetically-derived vaccines and anti-microbials. It also develops clean water technologies using microbial fuel cells; and sustainable agricultural products. Synthetic Genomics, Inc. was formerly known as Synthetic Genomic Solutions, Inc. The company was founded in 2005 and is base...
11149 North Torrey Pines Road
La Jolla, CA 92037
Founded in 2005
Key Executives for Synthetic Genomics, Inc.
Chief Executive Officer and Director
Co-Founder, Executive Chairman and Co-Chief Scientific Officer
Co-Founder, Co-Chief Scientific Officer and Director
Co-Founder, Executive Vice President, General Counsel and Director
Co-Founder, Chief Business Officer and Director
Compensation as of Fiscal Year 2015.
Synthetic Genomics, Inc. Key Developments
Synthetic Genomics, Inc. Presents at JPMorgan 34th Annual Healthcare Conference, Jan-13-2016 10:00 AM
Jan 6 16
Synthetic Genomics, Inc. Presents at JPMorgan 34th Annual Healthcare Conference, Jan-13-2016 10:00 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States. Speakers: Oliver Steffen Fetzer, Chief Executive Officer and Director.
Synthetic Genomics, Inc. Presents at Boston Biotech East West CEO Conference, Jan-10-2016 09:30 AM
Jan 1 16
Synthetic Genomics, Inc. Presents at Boston Biotech East West CEO Conference, Jan-10-2016 09:30 AM. Venue: Four Seasons Hotel, 757 Market St., San Francisco, CA 94103, United States. Speakers: Oliver Steffen Fetzer, Chief Executive Officer and Director.
Synthetic Genomics Expands Multi-Year Research and Development Agreement with Lung Biotechnology PBC
Sep 24 15
Synthetic Genomics has expanded its multi-year research and development agreement with Lung Biotechnology PBC. The contract has been signed to develop transplantation-ready pig organs using synthetic genomic advances. Both firms initially focused efforts on lung diseases and will now also include kidney diseases. Under the contract, SGI will receive royalties and milestones from the development and commercialization of the organs.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 22, 2015